Candel Therapeutics plans to test Bionaut’s tiny robots to treat brain tumors

The VC-backed microrobotics startup Bionaut Labs has entered into a strategic collaboration with Candel Therapeutics.

Candel (NSDQ:CADL) — a biopharma focused on oncolytic viral immunotherapies — will explore the use of Bionaut Labs’ miniature remote-controlled robots. Could the robots help deliver Candel’s oncolytic viral immunotherapy agents to certain brain tumors?

Founded in 2016, Bionaut Labs has focused on developing new modalities for treating central nervous system disorders since its inception.

Now, Bionaut will work with Candel to further the preclinical development of a micro-robotic system that can deliver oncolytic viruses directly to brain tumors, including high-grade gliomas.

“Bionaut designed its platform to provide accurate and safe access to hard-to-reach locations in the CNS,” said Michael Shpigelmacher, Bionaut Labs’ CEO.

Executives at Bionaut were impressed with Candel’s presence in …

Read more
  • December 15, 2021
  • 0

Inside Candel Therapeutics adenovirus and HSV immunotherapy platforms

Candel Therapeutics (NSDQ:CADL) recently announced that it had entered a strategic collaboration with microrobotics startup Bionaut Labs (Los Angeles) to explore precision-targeted delivery of oncolytic viral immunotherapies.

To learn more about the company, we reached out to Candela’s  Dr. Paul Peter Tak, president and CEO of the company.

Candel Therapeutics has two viral immunotherapy platforms, one based on adenovirus and another on herpes simplex virus (HSV). “Both of which are designed to be locally administered, have direct cancer-killing activity and elicit both local and systemic anti-tumor immune response,” Tak said.

The company believes these viral immunotherapies induce immune cells that target patients’ specific tumor antigens. As a result, such therapies could potentially “improve responses in immunologically ‘hot’ tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed “cold” tumors with limite…

Read more
  • December 15, 2021
  • 0